RS Crum Inc’s Calidi Biotherapeutics CLDI Stock Holding History

RS Crum Inc’s Portfolio CLDI Stock Details CLDI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-2,702	Closed	-$7.35K	–	103
2026 Q2	$7.35K	Buy	2,702 +186	+7%	+$601	﹤0.01%	103
2026 Q1	$9.6K	Buy	2,516 +1,250	+99%	+$15K	﹤0.01%	102
2025 Q4	$23.7K	Buy	1,266 +312	+33%	+$7.34K	﹤0.01%	97
2025 Q3	$23.2K	Buy	+954	New	+$64.8K	0.01%	99
2025 Q2	–	Sell	-288	Closed	-$31.3K	–	92
2025 Q1	$31.3K	Buy	288 +77	+36%	+$14K	0.01%	88
2024 Q4	$46.5K	Buy	+211	New	+$63.3K	0.01%	90
2024 Q3	–	Sell	-137	Closed	-$52.7K	–	96
2024 Q2	$52.7K	Buy	137 +131	+2,183%	+$66.9K	0.01%	92
2024 Q1	$6.13K	Buy	+6	New	+$9.8K	﹤0.01%	81

Other funds holding CLDI

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

RS Crum Inc's CLDI Position: Q3 2026 in Review

RS Crum Inc sold out of Calidi Biotherapeutics (CLDI) in Q3 2026, closing a stake of 2,702 shares — an estimated $7.35K sold.

RS Crum Inc first reported a position in CLDI in Q1 2024 and held it in 8 quarters. The position peaked at $52.7K in Q2 2024. 1 fund tracked by Wall St. Rank holds CLDI as of Q3 2026.

RS Crum Inc reported no remaining Calidi Biotherapeutics position as of Q3 2026 after selling out during the quarter.
RS Crum Inc sold 2,702 Calidi Biotherapeutics shares in Q3 2026, an estimated $7.35K.
RS Crum Inc first reported a position in Calidi Biotherapeutics in Q1 2024 and held it in 8 quarters.
RS Crum Inc's Calidi Biotherapeutics position peaked at $52.7K in Q2 2024.
1 fund tracked by Wall St. Rank held Calidi Biotherapeutics as of Q3 2026.

Based on RS Crum Inc's 13F filing for Q3 2026, filed 19 Oct 2026.